Value in Health Regional Issues: Cost-Effectiveness of Novel Kidney Disease Biomarker Screening

IgA nephropathy (IgAN) is a leading cause of end-stage kidney disease across the world. A new paper in Value in Health Regional explores the cost-effectiveness of screening for IgAN in Japan using novel biomarkers. Using an analytical decision model, researchers found that screening could substantially cut healthcare costs.

According to the authors, “Our results suggested that screening for IgAN with novel biomarkers can help diagnose IgAN in the early stages and thus provide timely and appropriate therapy to participants and help prevent induction of dialysis because of IgAN. To our knowledge, this is the first study to conduct a cost analysis on the IgAN screening method.”

To register with ISPOR and read the full paper, click here.

(Source: Value in Health Regional Issues, May 23^rd, 2022)